In January 2026, MEDIPOST Inc., the U.S. affiliate of South Korea‑based regenerative medicine and biotechnology company MEDIPOST Co., Ltd., successfully closed a $140 million funding round aimed at accelerating late-stage clinical development and operational growth. This capital infusion was led by Skylake Equity Partners and Crescendo Equity Partners, with participation from a leading Korean growth equity fund. The funds are intended to support MEDIPOST’s anticipated Phase III clinical trial of its allogeneic, umbilical cord blood-derived mesenchymal stem cell therapy for symptomatic cartilage defects in knee osteoarthritis, as well as expansion of its scientific, manufacturing, and infrastructure capabilities.
Alongside this strategic financing, MEDIPOST reached another noteworthy milestone with its CellTree® cord blood bank surpassing 330,000 units stored, reflecting sustained commercial traction in private cord blood banking and the accumulation of a substantial biological resource base. Cord blood contains both hematopoietic stem cells, which form all blood cell types, and mesenchymal stem cells, which have potential applications in regenerative therapies beyond traditional transplant use.
Cord Blood Inventory That Stands Out Globally
MEDIPOST’s milestone of storing more than 330,000 cord blood units through its CellTree® network represents more than just growth in absolute numbers. It places the company firmly among the larger private cord blood banks in the world, a noteworthy achievement in a market where scale correlates with clinical relevance, research leverage, and competitive positioning.
For context, some of the most established private cord blood banks globally have reported the following inventory figures:
-
Cord Blood Registry (CBR), long recognized as the largest private cord blood bank globally, has stored well over 1,000,000 cord blood and cord tissue units, maintaining a leading share of the U.S. private banking market.
-
ViaCord, another major U.S. private bank, currently stores more than 500,000 units, making it one of the top banks by units stored and a direct comparison point for MEDIPOST’s inventory scale.
While some private and public banks in China and Southeast Asia operate at even larger scales, with total inventories in the hundreds of thousands or millions of units, MEDIPOST’s CellTree inventory situates it competitively in the top tier of private global cord blood repositories. Total cord blood and tissue units stored across all private banks worldwide now exceeds 8.1 million, illustrating the immense scale of the overall industry and the value of being among the larger individual holders of stored units.
This scale matters because larger inventories not only enhance the likelihood of future clinical application and research use, but they also contribute to broader market influence and confidence among prospective customers planning for potential future health needs. Larger inventories can also attract strategic partnerships, research collaborations, and cross-border utilization opportunities that smaller banks may find more challenging to secure.
Why This Matters to the Broader Cord Blood Market
The cord blood banking sector is a foundational component of the larger regenerative medicine ecosystem. Globally, there are over 6.75 million cord blood and tissue units stored across public and private banks, with private banks maintaining a majority of that inventory. This scale of biopreservation underpins a range of therapeutic and research activities, from hematopoietic stem cell transplantation to emerging applications in personalized and regenerative medicine. (businesswire.com)
Market forecasts suggest the cord blood and tissue banking industry will continue expanding due to increasing awareness of stem cell therapies, supportive healthcare policies, and growing demand for personalized medicine solutions. In regions such as the Asia Pacific, where rising disposable incomes and birth rates coincide with regulatory support, growth projections remain robust. Furthermore, consolidation among major global players has positioned larger banks to manage extensive inventories and offer diversified services beyond mere storage.
For MEDIPOST, crossing the 330,000-unit threshold enhances its strategic position among global cord blood operators. A large and well-managed inventory strengthens its ability to support therapeutic development, foster research collaborations, and provide long-term value to families choosing cord blood banking for future medical use. It also signals confidence from customers and stakeholders in the bank’s processing, cryopreservation, and quality assurance capabilities.
At the same time, the successful capital raise provides the company with resources needed to advance clinical programs into later stages, aligning the commercial cord blood business with clinical innovation. This combination of storage scale and therapeutic development ambition underscores a broader trend: cord blood banking is evolving from a pure storage service to an integrated platform contributing to next-generation regenerative medicine.
As the cord blood market continues to grow and innovate, developments like MEDIPOST’s fundraise and inventory milestone not only reflect internal corporate progress but also mirror macro trends shaping the industry at large. Investors, clinicians, and industry stakeholders will want to watch this trajectory closely as private cord blood banks expand capacity and integrate with clinical pipelines.
